JPRN-jRCT1080224940已完成3 期
An open-label, single-group, multi-center, Phase III study to evaluate the efficacy and safety of ST-HT when administered 3 times daily for 3 days to the patients with common cold
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 148
研究概览
简要总结
The drug ameliorated a variety of symptoms in patients with common cold and was well tolerated in terms of safety and was considered safe for over-the-counter use.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 15age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Common cold patient diagnosed by the invetigator
- •2. age: 15 years old and above at the time of giving consent
- •3. Patient who gives written consent
排除标准
- •1. Patinet who was diagnosed as influenza by the investigator
- •2. Patient with underlying chronic upper airway disease or lowe ariway disease
- •3. Patine with seasonal nasal allergy during taking the study medication
研究者
相似试验
已完成
1 期
Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).Wilson's DiseaseNCT06128954Orphalan26
已完成
1 期
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationGeographic AtrophyNCT04615325Hoffmann-La Roche37
尚未招募
早期 1 期
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination FormulationClostridium TetanusNCT06360250Changchun BCHT Biotechnology Co.190
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin LymphomaB-cell Non-Hodgkin LymphomaNCT03671018Hoffmann-La Roche422
已完成
早期 1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid TumoursAdvanced or Metastatic Solid TumoursNCT05021120Akesobio Australia Pty Ltd67